Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 63187-571

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 63187-571). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Valhyctz Fig1)

A line graph depicting the probability of achieving systolic blood pressure (SBP) less than 140 mmHg at week 8, plotted against baseline SBP values ranging from 140 to 180 mmHg. The graph compares four groups: Valsartan and Hydrochlorothiazide 320 mg/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, with each represented by distinct markers and lines.*

FDA Label Image

Figure 2: Probability Of Achieving Diastolic Blood Pressure <90 Mmhg At Week 8 (Valhyctz Fig2)

A line graph depicting the probability of achieving diastolic blood pressure (DBP) below 90 mmHg relative to baseline DBP values ranging from 90 to 110 mmHg. The graph compares four groups: Valsartan and Hydrochlorothiazide 320 mg/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, showing decreasing probability trends as baseline DBP increases.*

FDA Label Image

Figure 3: Probability Of Achieving Systolic Blood Pressure <130 Mmhg At Week 8 (Valhyctz Fig3)

A line graph showing the probability of achieving systolic blood pressure (SBP) less than 130 mmHg at week 8 versus baseline SBP (mmHg). Four groups are compared: Valsartan and Hydrochlorothiazide 320 mg/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, with probabilities decreasing as baseline SBP increases.*

FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure <80 Mmhg At Week 8 (Valhyctz Fig4)

A line graph depicting the probability of achieving diastolic blood pressure below 80 mmHg at Week 8. The x-axis represents baseline DBP in mmHg (90-110), and the y-axis shows percentage (%) achieving goal. Four treatments are compared: Valsartan and Hydrochlorothiazide 320 mg/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, with Valsartan and Hydrochlorothiazide showing the highest probability across baseline values.*

FDA Label Image

63187-571-30 (Valhyctz Fig5)

Label for Valsartan HCTZ 80 mg / 12.5 mg film-coated tablets by Proficient Rx LP. The label states a quantity of 30 tablets, each containing valsartan USP 80 mg and hydrochlorothiazide USP 12.5 mg. Tablets are described as light orange, ovaloid, biconvex with beveled edges, debossed with 'I' on one side and '61' on the other. Manufactured by Aurobindo Pharma Limited, Hyderabad, India.*

FDA Label Image

Valsartan Chemical Structure (Valhyctz Str1)

Chemical structure of Valsartan, one of the active ingredients in the combined pharmaceutical product Valsartan and Hydrochlorothiazide.*

FDA Label Image

Hydrochlorothiazide Chemical Structure (Valhyctz Str2)

Chemical structure of the active ingredient Valsartan, showing its molecular configuration with chlorine, sulfonamide, and hydantoin functional groups as part of its chemical formula.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.